Klinikiniai Sprendimai UAB

Research site

Lithuania Vilties G. 4-46, Alytaus M. Sav., 63200 Alytus, Lithuania

2 trials recruiting
Arteriosclerosis · Chronic kidney disease · Cardiovascular disorder
Adult patients

About Specializations

Klinikiniai Sprendimai UAB in Alytus, Lithuania specialises in clinical trials of conditions such as Arteriosclerosis, Chronic kidney disease, Cardiovascular disorder, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Vilties G. 4-46, Alytaus M. Sav.63200 AlytusLithuania

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 6

More sites in Alytus Lithuania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

7 clinical trials

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Lithuania

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

Lithuania

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

Lithuania

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug

Lithuania

Participants:18–64 years · 65+ years
Substances:Evolocumab
Sponsor:Amgen Inc.

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Lithuania

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Novartis Pharma AG

Contact Research Centre

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug

Lithuania

Participants:18–64 years · 65+ years
Substances:Inclisiran
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Lithuania

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites